Collectively, these findings highlight the intricate relationship between GARS1 and immune cell activation in the context of anti-cancer immune responses, thereby providing valuable insights for further investigations into GARS1-related tumor immunotherapy. The gene discussed is GARS1; the disease is neoplasm.